LLY
ELI LILLY & Co
NYSE · Healthcare · Drug Manufacturers - General · US
$1,409.38
−0.11%Price chart
Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3
Key dataNov 3, 2026
Open$1,399.63
From 52W high−0.58%
Volume2.71M
Market cap$1.33T
P/E (TTM)45.6x
P/S (TTM)15.3x
Div yield0.47%
Key dataNov 3, 2026
Open
$1,399.63
From 52W high
−0.58%
Volume
2.71M
Market cap
$1.33T
ValuationView details →
P/E (Fwd)
30.4x
EV/EBITDA
30.6x
P/E (TTM)
45.6x
RSI (14)
77.1
MomentumView details →
1D Return
−0.11%
YTD Return
+32.22%
SummaryUpdated Sep 1, 2026
Eli Lilly and Company (NYSE:LLY) is a major American pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company has evolved from a small Indianapolis pharmacy into one of the world's largest pharmaceutical manufacturers, with a particular focus on diabetes care, oncology, immunology, and neuroscience. Lilly went public in 1972 and has established itself as a leader in innovative drug development, with recent breakthrough success in diabetes and obesity treatments that have transformed both the company's financial performance and market position in the healthcare sector.
Similar companies
Latest newsMore news →
Republican Ron Schutz, candidate for Minnesota attorney general, disclosed a stock portfolio of more than $10,000 in each of 174 companies worth at least $1.74 million, creating potential conflicts of interest with corporations the office litigates.36d agoEli Lilly will present Phase 2 results for eloraTZP, a combination of eloralintide and tirzepatide, at EASD 2026 in Milan on Sept. 30, 2026.37d agoEli Lilly will present Phase 3 results for its experimental once-weekly injection retatrutide at the EASD 2026 symposium in Milan on Sept. 30, 2026.37d ago